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ECONOMIC EVALUATION OF EZETIMIBE COMBINED WITH 
SIMVASTATIN FOR TREATMENT OF PRIMARY 
HYPERCHOLESTEROLAEMIA
Van Nooten F1, Davies GM2, Jukema JW3, Liem AH4, Hu XH5
1United BioSource Corporation, London, UK, 2Merck and Co, Blue Bell, PA, USA, 3Leiden 
University Medical Center, Leiden, The Netherlands, 4Oosterscheldeziekenhuizen, Goes, The 
Netherlands, 5Merck & Co., Inc, West Point, PA, USA
INTRODUCTION: Coronary heart disease (CHD) is a leading cause of death in the 
Western world. Hypercholesterolemia is an important risk factor for CHD. Ezetimibe, 
a cholesterol absorption inhibitor, can be used in combination with statins to improve 
cholesterol levels. OBJECTIVES: The aim was to assess cost-effectiveness of ezetimibe 
combined with simvastatin compared to atorvastatin or simvastatin monotherapy for 
second line treatment of primary hypercholesterolaemia in the Dutch population. 
METHODS: A published Markov model (Cook et al 2004) was adapted to evaluate 
two lipid treatment scenarios in The Netherlands. Baseline patient data from the Dutch 
EASEGO study were used. The ﬁrst scenario was based on this study: patients not 
reaching low-density-lipoprotein cholesterol (LDL-C) goal on atorvastatin 10 mg 
(A10) or simvastatin 20 mg (S20) were included. These patients were modeled using 
a doubled dose, or addition of ezetimibe 10 mg to generic simvastatin (eze10/sim20). 
The second scenario was based on Dutch guidelines. All patients were not meeting 
their LDL-C goal on simvastatin 40 mg (S40) and were switched to atorvastatin 
40 mg (A40), or ezetimibe 10 mg was added to generic simvastatin (eze10/sim40). 
Key effectiveness measure was change in ratio of total cholesterol to high-density-
lipoprotein cholesterol. Model parameters were derived from published literature 
and guidelines. One-way sensitivity analyses were performed for key model parame-
ters. RESULTS: Based on EASEGO the incremental cost-effectiveness ratio for eze10/
sim20 was a3,497 per quality-adjusted life year (QALY) compared to A20 and 
a26,417/QALY compared to S40. Based on Dutch guidelines, eze10/sim40 was domi-
nant, and can be seen to be cost-saving compared with A40 (a3,675/QALY). These 
results were not very sensitive to changes in input parameters. CONCLUSIONS: Eze/
sim can be considered a cost-effective treatment (EASEGO versus A20 or S40) and in 
light of the Dutch guidelines (versus A40) even cost-saving. The addition of ezetimibe 
to simvastatin is a valuable second line treatment option.
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COST EFFECTIVENESS OF MPLANTABLE LOOP RECORDERS (ILRS) FOR 
UNEXPLAINED SYNCOPE DIAGNOSTICS IN FRANCE
Debroucker F, Graciet A
Medtronic France, Boulogne Billancourt Cedex, France
OBJECTIVES: Unexplained Syncope patients have 1.6 times the mortality risk of 
the average population. The “Eastbourne Syncope Assessment Study” (EaSyAS; 
Farwell 2004) is an RCT which demonstrated a signiﬁcantly higher diagnostic 
yield in unexplained syncope patients using ILRs (Reveal, Medtronic) (34/101 
Patients diagnosed (33.7%) versus a conventional diagnostic strategy (4/97 Patients 
diagnosed (4.1%); p  0.001) after a mean follow-up period of 9 months. The study           
also included detailed health care utilisation analysis, ultimately demonstrating 
a reduced cost-per-correct-diagnosis under the UK setting and signiﬁcant reductions 
in the overall volume of diagnostic tests. We sought to explore potential cost implica-
tions of ILR use in this patient population, from the perspective of the French Social 
Security. METHODS: We used EaSyAS to assess the type and volume of diagnostic 
tests used. Direct medical costs were derived from the 2008 CCAM Procedure Tariff 
and DRG Tariff. Reveal selling price was used to assess ILR cost. RESULTS: The 
cost of a successfully diagnosing an unexplained syncope patient with Reveal is 
4.7 times lower than the equivalent cost using a conventional strategy. This allows 
for a moderate ICER equal to a2535.60 on a cost-per-diagnosis basis.Two univariate 
sensitivity analysis on the device cost and the procedures cost showed little impact 
on the ICER. CONCLUSIONS: Although this analysis was based on UK short term 
data, its results are consistent with analyses performed in other developed countries. 
The analysis demonstrated an ICER below a4,000 on a cost-per-diagnosis basis. This 
could mean that ILR use in France has the potential for signiﬁcant cost-savings in this 
patient population. The upcoming FREnch Syncope study on Holter monitoring 
(FRESH) should allow for a more precise assessment of cost-savings achieved with 
ILRs in France.
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COST EFFECTIVENESS OF STATIN THERAPY IN SOUTH KOREA
Bae EY1, Bae S2, Lim MK3, Choi SE4
1Sangji University, Gangwondo, South Korea, 2Health Insurance Review and Assessment 
Service, Seoul, South Korea, 3Health Insurance Review Agency, Seoul, Seocho-Gu, South 
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OBJECTIVES: The Korean government announced in December 2006 that only 
medications with good value for money, based on cost-effectiveness analysis, will be 
reimbursed in the Korean National Health Insurance program. As a pilot program, 
Health Insurance Review and Assessment Service (HIRA) conducted cost-effectiveness 
analysis of already listed medications, triptans and statins, in 2007. The purpose of 
this study was to examine cost-effectiveness of statin medications in Korea. 
METHODS: We conducted systematic review(s) to evaluate the clinical signiﬁcance 
of 7 statin medications available in Korea: Atorvastatin, Lovastatin, Fluvastatin, 
Pitavastatin, Pravastatin, Rosuvastatin, and Simvastatin. Meta-analyses were con-
ducted to summarize comparative effectiveness of statin medications. Costs of relevant 
diseases (Angina, MI, stroke) were estimated based on the claims data. Lifetime cost 
and health outcomes associated with statin treatment were projected based on a 
Markov model. A societal perspective was taken. Target population was 55-year-old 
Korean patients whose cholesterol level is elevated, with (secondary prevention) and 
without (primary prevention) previous history of CHD or CVD. RESULTS: The result 
of the Meta-analysis suggests that statin therapy is associated with reduced relative 
risk of all cause mortality, CVD mortality, CHD mortality, MI, and angina, but not 
stroke mortality at statistically signiﬁcant level. However, currently available evidence 
was not enough to suggest whether the clinical effectiveness of Atorvastatin, Fluvas-
tain, Lovastatin, Pravastatin, and Simvastatin was statistically signiﬁcantly superior 
than the rest of the statin. No published study was found regarding Pitavastain on 
CHD/CVD outcomes; Rosuvastatin study on CHD/CVD outcomes was only con-
ducted among limited population. In Primary prevention, the incremental cost-
 effectiveness ratios (ICERs) were KRW /LYG and KRW/QALY; in secondary 
prevention, the ICER decreased to KRW /LYG and KRW/QALY. The results of the 
sensitivity analyses were consistent with those of base case. CONCLUSIONS: Under 
current price, Statin therapy are less cost-effective when used as a primary prevention, 
compared with secondary prevention.
PCV110
COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED 
THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) 
AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY
Weitz J1, Bernard L2, Wakeford C3
1McMaster University, Hamilton, ON, Canada, 2Cornerstone Research Group, Burlington, 
ON, Canada, 3Sanoﬁ-Aventis, Laval, QC, Canada
OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) comparing 35 days of 
prophylaxis (extended enoxaparin) with short term prophylaxis (12 days enoxaparin) 
for thromboprophylaxis of venous thromboembolism (VTE) in patients undergoing 
elective total hip replacement (THR) surgery at high risk for VTE. The analysis was 
for a lifetime horizon from a Canadian payer perspective. METHODS: A Markov 
model was developed to estimate incremental cost per life year gained and quality-
adjusted life year (QALY) gained. Clinical outcomes considered in the model included 
symptomatic deep-vein thrombosis (DVT), pulmonary embolism (PE), post-throm-
botic syndrome (PTS), and major bleeding associated with thromboprophylaxis. 
Treatment-speciﬁc event rates for DVT, PE and major bleeding were derived as pooled 
estimates from 3 pivotal clinical trials of extended enoxaparin versus short-term 
enoxaparin. Ontario resource utilization and unit costs derived from published litera-
ture were applied to trial-based drug treatment and events to estimate the costs of 
drug acquisition and administration, and diagnosing and managing DVT, PE, PTS 
and major bleeding. Utility weights used in the calculation of QALYs were also derived 
from the literature. RESULTS: Compared with short-term enoxaparin extended 
enoxaparin resulted in 39.6 fewer VTE events per 1,000 patients and a gain of 
approximately 0.01 life years and QALYs per patient. Total costs were higher for 
extended enoxaparin, resulting in an incremental cost of CAD$22,675 per life year 
gained and $26,254 per QALY gained (discounted at 5% per year). The results were 
most sensitive to assumptions regarding the percentage of patients requiring home 
nursing to administer enoxaparin. CONCLUSIONS: In patients undergoing elective 
THR surgery, extended thromboprophylaxis with enoxaparin reduces the risk of VTE 
and provides favourable cost-effectiveness ratios compared with short-term thrombo-
prophylaxis only with enoxaparin. The analysis demonstrates that extended throm-
boprophylaxis with enoxaparin in patients undergoing THR surgery represents a 
cost-effective use of resources.
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A PATIENT’S VIEW OF THE COST-EFFECTIVENESS OF USING LOW-
DOSE ASPIRIN FOR CVD (CARDIOVASCULAR DISEASE) PRIMARY 
PREVENTION IN MIDDLE-AGED MEN IN THE UK
Amirsadri-Naeini M, Jackson PR
University of Shefﬁeld, Shefﬁeld, South Yorkshire, UK
OBJECTIVES: To evaluate from the patient’s perspective, the ICERs (Incremental 
Cost-Effectiveness Ratio) of using aspirin as UK guideline based CVD (Cardiovascular 
Disease) primary prevention in middle-aged men compared to no pharmacotherapy. 
METHODS: A Markov-model was used to investigate the cost-effectiveness of low-         
dose aspirin in a hypothetical population of initially healthy men (55 years old) with 
15% CVD risk, up to 100 years of age or death. For the base-case scenario, it was 
assumed that all would take OTC (Over The Counter) aspirin. Those experiencing a 
CVD event would be switched to POM, (Prescription Only Medicine) aspirin plus 
statin. After a bleeding event, aspirin would be permanently discontinued. If the event 
was GI-bleeding, aspirin was replaced by POM clopidogrel. All were assumed to pay 
prescription charges until aged 59. The main effect outcomes are QALYs (Quality-
Adjusted Life Years) and LYG (Life-Years Gained). The main costs are prescription 
charges, purchase of OTC aspirin, income loss and travel costs. Published studies on   
the efﬁcacy of aspirin and clopidogrel for primary prevention, their side-effects and 
the NICE technology assessment report “Statins for the Prevention of Coronary 
Events” published in 2005 were used as sources for transition probabilities, relative 
risks and utility values. Cost data were sourced from the NHS and “HM Revenue & 
Customs” databases, and average retail UK prices. RESULTS: The estimated incre-
mental cost-effectiveness is: cost-saving of £200.44 (95%CI: £142.10 to £264.48), 
gain of 0.044 (95%CI: 0.005–0.075) QALYs and loss of 0.017(95%CI: 0.069 to 
0.025) LYG. In univariate analyses, baseline CVD risk, income loss and aspirin effect 
on transitions from healthy to haemorrhagic stroke, cerebro-vascular death and GI-
bleeding had the greatest impact on the results. CONCLUSIONS: Low-dose aspirin 
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therapy for primary CVD prevention saves patients money and increases QALYs, but 
at the expense of lost life years.
PCV112
COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN 
ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM 
AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP 
REPLACEMENT IN IRELAND
McCullagh L1, Tilson L1, Walsh C2, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, 
Ireland
OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban and dabigatran com-
pared to enoxaparin as venous-thromboembolism prophylaxis post total hip replace-
ment (THR), from the Irish health payer perspective. METHODS: A hybrid model 
combing an acute phase decision tree (180 days post-surgery) and a chronic phase 
Markov model (patient lifetime) was developed using TreeAge Pro 2008®. Outcome 
measures were QALYs and LYGs. Future costs and outcomes were discounted at 4%. 
Treatment efﬁcacy and major bleeding probabilities were derived from pivotal clinical 
trials. Thromboprophylaxis independent probabilities were identiﬁed via a literature 
search. A one-way sensitivity analysis of all probabilities was completed using the 
upper/lower bounds of the 95% conﬁdence interval where available; otherwise point 
estimates were varied o 50%. A probabilistic sensitivity analysis (PSA) using second 
order Monte Carlo simulation was performed. Probabilities were assigned beta distri-
butions. Dirichlet distributions were adopted for multibranch nodes. Utilities and 
direct costs were given beta and lognormal distributions respectively. RESULTS: 
Basecase Analyses: Rivaroxaban dominated both dabigatran and enoxaparin. The 
incremental cost-effectiveness ratios for dabigatran relative to enoxaparin were a1885 
per LYG and a1811 per QALY. One-Way Sensitivity Analysis: The model was robust 
to all but three probability variations; the probabilities that a proximal deep vein 
thrombosis (DVT) will occur on dabigatran, a pulmonary embolism or proximal DVT 
will occur on enoxaparin. PSA: At a a45,000/QALY threshold, the probability that 
rivaroxaban was the most cost-effective strategy was 67%, followed by dabigatran 
(19%) and enoxaparin (14%). A cost-effectiveness plane illustrating scatterplots for 
rivaroxaban versus enoxaparin and dabigatran versus enoxaparin was produced. 
Overlap indicates uncertainty that rivaroxaban is more cost-effective than dabigatran. 
CONCLUSIONS: Basecase analyses indicate that rivaroxaban is more cost-effective 
than enoxaparin or dabigatran. PSA indicates that rivaroxaban is the most cost-
 effective strategy at a a45,000/QALY threshold; however there is uncertainty regard-
ing this strategy being more cost-effective than dabigatran.
PCV113
COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN IN 
EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN 
MAJOR ORTHOPEDIC SURGERY IN POLAND
Kawalec P1, Kuzma J1, Glogowski C2, Krzyzanowska A3
1Centrum HTA, Krakow, Poland, 2GSK Commercial Sp. z o.o, Warsaw, Poland, 
3GlaxoSmithKline Poland, Warsaw, Poland
OBJECTIVES: To assess clinical effectiveness and cost–effectiveness of fondaparinux 
vs enoxaparin (40 mg or 30 mg twice a day) in extended prophylaxis (administration 
for 30 days) of venous thromboembolism in patients after major orthopedic surgery 
(knee arthroplasty, hip arthroplasty, hip fracture) in Poland. METHODS: Systematic 
review and clinical effectiveness analysis according to Polish HTA Guidelines were 
performed. Only RCTs with high credibility assessment were included in the systematic 
review (according to EBM). Costs valid from public payer’s perspective (National 
Health Fund) were taken into account and were based on data from 2007. Costs of 
pharmacotherapy were estimated with 100% reimbursement (lump sum patient 
payment 3.2 PLN). Both health effects and costs were discounted with ﬁve percent rate 
applied. Analysis was performed within ﬁve percent year time horizon. Sensitivity 
analysis was performed. RESULTS: The analysis showed that prophylaxis with 
fondaparinux was more expensive than treatment of enoxaparin in greater (40 mg) and 
in smaller (30 mg) doses by 211 PLN or 98 PLN respectively; however brought better 
health outcomes by 0.01 LYGs and 0.003 LYGs per patient. ICERs were estimated at 
21,603 PLN and 29,950 PLN, respectively, both below cost-effectiveness threshold in 
Poland (91,000 PLN  3 times GDP per capita). The sensitivity analysis proved that 
costs of pharmacotherapy with fondaparinux and enoxaparin had the biggest impact 
on results. CONCLUSIONS: Extendeding prophylaxis of venous thromboembolism 
with fondaparinux compared with enoxaparin in patients undergoing major orthope-
dic surgery is cost-effective option from public payer’s perspective in Poland.
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DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY 
PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING 
MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS
Boersma C1, Kappelhoff BS2, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2Boehringer Ingelheim bv, Alkmaar, 
The Netherlands
OBJECTIVES: Dabigatran etexilate (DBG) is a new oral direct thrombin inhibitor for 
prophylaxis of venous thromboembolism (VTE) in patients who have undergone total 
hip replacement (THR) or total knee replacement (TKR) surgery. Advantages of DBG 
over parenteral prophylaxis might include but are not limited to reduced resource use 
for 1) teaching patients to self-inject; 2) home-care visits for parenteral administration; 
and 3) absence of Heparin Induced Thrombocytopenia (HIT). Based on proven non-
inferiority, the aim of this study was to conduct a cost-minimization analysis of oral 
DBG versus parenteral low-molecular weight heparin (LMWH) and Fondaparinux 
formulations from the perspective of the Dutch National Health Service. METHODS: 
A retrospective cohort study was conducted to measure resource use associated with 
parenteral prophylaxis. Drug-utilization data were combined with local unit costs. 
Probabilistic sensitivity analysis was performed to account for uncertainty around 
relevant parameters included. RESULTS: Home-care visits for parenteral administra-
tion problems were required by 9.9% (95%CI: 6.4–13.4) and 9.6% (95%CI: 5.8–
13.4) of THR and TKR patients, respectively. Based on costs for 1000 patients treated 
with DBG versus LMWHs, per patient cost-savings with DBG were estimated at 
a24.63 (95%CI: 0.56–54.19) and a18.39 (95%CI: 2.54–41.52) for THR and TKR, 
respectively. The probability that DBG would be cost-saving is 97.1% and 95.6% for 
THR and TKR, respectively. These cost-savings were even higher when including 
Fondaparinux with per patient cost-savings of a84.87 (95%CI: 58.04–117.64) and 
a33.41 (95%CI: 12.27–57.36) for THR and TKR, respectively. Separate calculations 
for DBG versus Nadroparin and Dalteparin in THR resulted in a probability of achieving 
cost-savings with DBG of 19.0% and 100%, respectively. For TKR these probabilities 
for DBG versus Nadroparin and Dalteparin were estimated at 37.0% and 100%. 
CONCLUSIONS: Thromboprophylaxis with DBG is cost-saving in patients undergo-
ing THR/TKR for the perspective of the Dutch National Health Service.
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TIROFIBAN IS MORE COST-EFFICIENT THAN ABCIXIMAB IN 
ACHIEVING ST-SEGMENT RESOLUTION FOLLOWING ACUTE 
MYOCARDIAL INFARCTION
DeMaria J1, Wong B2, Valgimigli M3
1Iroko Pharmaceuticals, Philadelphia, PA, USA, 2Bruce Wong & Associates Inc., Radnor, PA, 
USA, 3Azienda Opedaliera Universitaria di Ferrara, Ferrara, Italy
OBJECTIVES: Glycoprotein IIb/IIIa inhibitors are highly effective inhibitors of platelet 
aggregation. The MultiStrategy trial showed Tiroﬁban or Abciximab were similarly 
efﬁcacious in resolving ST-segment elevation at 90 min post intervention following 
Acute Myocardial Infarction. As combination therapy to inhibit platelet function and 
the coagulation cascade to improve cardiovascular outcome is increasingly common 
in Acute coronary settings, the focus is turning to cost efﬁcient approaches. We 
undertook a pharmaco-economic analysis of the MultiStrategy study to identify the 
most cost-efﬁcient therapy. METHODS: Cost-minimization analysis of a randomized 
controlled trial, where costs are calculated only when between group statistical differ-
ences are identiﬁed. Direct medical resources (drugs, procedures, investigations, 
adverse effects and duration of stay) were prospectively collected within the case report 
form. Drug costs were average wholesale prices obtained from the manufacturer. 
RESULTS: Drug utilization and major procedural resources between groups was 
similar; Clopidogrel (p  0.71), Aspirin (p  0.18), Heparin (p  0.14); PCI; stents 
(p  0.81), guidewires (p  0.45), non serious adverse events (p  0.41), Bleeding 
(p  0.775), # Days in hospital (p  0.95). Duration of Tiroﬁban infusion was longer 
19.97h vs. 11.44h (p  0.000) whereas, amount of Glycoprotein inhibitor and number 
of required vials of drug was higher for Abciximab 23,491Mg v. 14,328Mg (p  0.000) 
and 2.933 v. 1.707 (p  0.000) respectively. The average calculated cost of Abciximab 
was higher than Tirﬁban 876.93 vs. a348.20 (p  0.000) or a196,787 total cost dif-
ference between study arms (n  361 patients per arm). CONCLUSIONS: All resource 
variables were similar between arms except for the randomized medication. No 
resource implications of medication side-effects or treatment duration were seen. 
Tiroﬁban is the more cost-efﬁcient Glycoprotein IIb/IIIa inhibitor in achieving ST-
segment resolution at 90min post intervention.
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COST-EFFECTIVENESS OF BIVALIRUDIN VERSUS HEPARIN PLUS 
GLYCOPROTEIN IIB/IIIA INHIBITOR IN THE TREATMENT OF ACUTE 
ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION—A HORIZONS 
TRIAL ANALYSIS USING UK VALUATIONS
Schwenkglenks M1, Szucs TD1, Brazier JE2, Blackman DJ3, Cyr P4, Olchanski N4, Stone GW5
1University of Basel, Basel, Switzerland, 2University of Shefﬁeld, Shefﬁeld, UK, 3Leeds General 
Inﬁrmary, Leeds, UK, 4Boston Healthcare Associates, Inc, Boston, MA, USA, 5Columbia 
University Medical Center, New York, NY, USA
OBJECTIVES: Primary percutaneous coronary intervention (PPCI) has become the 
preferred treatment option for acute ST-segment elevation myocardial infarction 
(STEMI). In the HORIZONS randomised controlled trial, anticoagulation with biva-
lirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) was associated with 
similar ischemic event rates and signiﬁcantly reduced bleeding events. Mortality at 30 
days and 1 year, in this indication. We estimated the incremental cost-effectiveness of 
bivalirudin in the HORIZONS trial. UK National Health Service valuations and per-
spective were applied. METHODS: A decision tree model compared the bivalirudin 
and heparin plus GPI strategies investigated in HORIZONS. It was combined with a 
Markov module to achieve a life-long time horizon. The health economic endpoint was 
cost per quality-adjusted life-year (QALY) gained. One-year clinical event rates and 
medical resource use parameters were derived from the HORIZONS dataset. Remain-
ing life expectancy and long-term cardiovascular treatment costs of ﬁrst-year survivors, 
unit costs, and utilities were drawn from published UK sources. Costs and effects were 
discounted at 3.5%. Extensive sensitivity analyses were performed. RESULTS: In 
the base case analysis, the bivalirudin strategy was dominant with an average saving 
of £450 per patient and an average survival gain of 0.09 QALYs per patient. Cumula-
tive costs in the bivalirudin and heparin plus GPI strategies were £12,318 and £12,769 
per patient, respectively. Patients lived 6.05 and 5.96 QALYs. A dominant or highly 
